Loading data for AVR — first visit, this takes a few seconds.
Anteris Technologies Global Corp.
8.42 +0.05 (0.60%)
- Market Cap
- $820.6M
- Volume
- 445K
- Dividend yield
- n/a
- Next earnings date
- Nov 12, 2026
Anteris Technologies Global Corp. (AVR) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $1.01M | n/a | +63.27% |
| EPS | -$0.30 | -$0.09 | +50.82% |
Metrics
- Bid
- 5.95
- Market Cap
- 821M
- Revenue (ttm)
- 2.24M
- Net Income (ttm)
- -104M
- n/a
- -1.96
- n/a
- -8.42
- P/B (ttm)
- 3.26
- P/S (ttm)
- 366.01
- Earnings Date
- Nov 12, 2026
- Ask
- 10.57
- Volume
- 444,982
- Avg. Volume (20D)
- 1,028,948
- Open
- 8.50
- Previous Close
- 8.37
- Day's Range
- 8.35 - 8.51
- 52-Week Range
- 3.30 - 11.05
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Anteris Technologies Global Corp.
View profile →Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Industry Medical Devices
Sector Healthcare
IPO Date Dec 13, 2024
Employees 174
Stock Exchange NasdaqGM
Ticker Symbol AVR
Website https://anteristech.com